Skip to Content

'
John F Ward, III, MD, FACS

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1991 Georgetown University, Washington, DC, MD, Medicine
1987 University of Notre Dame, Notre Dame, IN, BS With Honors, Biology

Postgraduate Training

6/2001-6/2003 Clinical Fellowship, Urologic-Oncology, Mayo Clinic, Rochester, MN, Dr. Horst Zincke, MD, PhD
7/1993-7/1998 Clinical Residency, Urology, Naval Medical Center, San Diego, CA
7/1991-6/1992 Clinical Internship, General Surgery, Naval Medical Center, San Diego, CA

Board Certifications

2010 American Board of Urology
7/1992 National Board of Medical Examiners

Experience/Service

Academic Appointments

Assistant Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 12/2006-9/2012
Assistant Professor, Department of Urology, Eastern Virginia School of Medicine, Norfolk, VA, 7/2003-7/2006

Administrative Appointments/Responsibilities

Chief, Department of Urology, Division of Surgery, Nevada Cancer Institute, Las Vegas, NV, 11/2004-6/2006
Assistant Department Head, Department of Urology, Division of Surgery, Naval Medical Center Portsmouth, Portsmouth, VA, 7/2003-7/2005
Director, Urologic Oncology, Urology, Naval Medical Center Portsmouth, Portsmouth, VA, 7/2003-7/2005
Department Head, Department of Urology, Division of Surgery, U.S. Naval Hospital Okinawa, Okinawa, Japan, 8/1999-7/2001
Director, Organ Transplantation, Division of Surgery, U.S. Naval Hospital Okinawa, Okinawa, Japan, 8/1999-7/2001

Consultantships

Advisory Board Member, Dendreon, Las Vegas, NV, 3/2006
Advisory Board Member, Abbott Laboratories, Chicago, IL, 10/2005
Advisory Board Member, Roche Laboratories, Scottsdale, AZ, 9/2005

Military or Other Governmental Service

Commission Resigned, Honorable, United States Navy, 7/2005
Naval Medical Center, Portsmouth, VA., United States Navy, 7/2003-7/2005
Admin. Assign, Univ. of Minn. ROTC, United States Navy, 7/2001-7/2003
Promoted, Commander, United States Navy, 7/2001
U.S. Naval Hospital, Okinawa, Japan, United States Navy, 8/1999-7/2001
Naval Medical Center, San Diego, CA, United States Navy, 7/1998-8/1999
Promoted, Lieutenant Commander, United States Navy, 6/1995
Naval Medical Center, San Diego, CA, United States Navy, 7/1993-7/1998
Marine Expeditionary Unit 31-Okinawa, Japan, United States Navy, 7/1992-7/1993
Naval Medical Center, United States Navy, 6/1991-7/1992
Promoted, Lieutenant, United States Navy, 5/1991

Institutional Committee Activities

Member, Clinical Research Committee, 9/2007-present
Member, Department of Urology CRC Review Committee, 7/2007-present
Member, Faculty Senate, 3/2007-present

Honors and Awards

2002 Young Investigator Scholarship, Academy of Molecular Imaging
1988-1989 Vice-President, Sophomore Medical Class, Georgetown University
1983-1987 University of Notre Dame Honors Program, University of Notre Dame

Professional Memberships

American Association for Cancer Research
Member, 2007-present
American Brachytherapy Society
Member, 2007-present
American Radium Society
Constitution and Bylaws Committee, 2007-present
American Radium Society
Membership and Credentials Committee, 2007-present
American Society of Clinical Oncology
Member, 2006-present
American Urological Association
Member, 1993-present
Societe Internationale d'Urologie
Candidate Member, 2007-present
Society of Government Service Urologists
Member, 1993-present
Society of Urologic Oncologists
Member, 2001-present
South Central Section of the American Urological Association
Member, 2007-present
Young Urologic Oncologists
Executive Committee Member, 2004-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Chen H, Liakou CI, Kamat AM, Pettaway CA, Ward JF, Tang DN, Sun J, Jungbluth AA, Troncoso P, Logothetis C, Sharma P. Anti-CTLA-4 therapy results in higher CD4(+)LCOS(hi) T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci USA 106:2729-2734, 4/2009.
2. Ward JF, Margulis V. Continuous improvement of TNM staging system for bladder cancer. Cancer 115:704-705, 4/2009.
3. Blana A, Brown SC, Chaussy C, Conti GN, Eastham JA, Ganzer R, Murat FJ, Pasticier G, Rebillard X, Rewcastle JC, Robertson CN, Thuroff S, Ward JF. High-Intensity Focused Ultrasound for prostate cancer: comparative definitions of biochemical failure. BJU Int 104(8):1058-62, 4/2009.
4. Ward JF, Nakanishi H, Pisters LL, Babaian RJ, Troncoso P. Cancer Ablation with regional templates applied to prostatectomy specimens from men who were eligible for focal therapy. BJU Int 104(4):490-7, 2009.
5. Ward JF, Nakanishi H, Babaian RJ, Troncoso P. In-field/out-field prostate cancer foci: multifocality and considerations for the application of focal prostate therapy. Journal of Urology 179(4):493, 04/01/2008, 4/2008.
6. Davis JW, Troncoso P, Ward JF, et al. Active Surveillance for clinically localized prostate cancer in the era of technology: Introduction of a prospective protocol into a high volume tertiary referral centre. European Urology Supplements 3:234, 03/01/2008, 3/2008.
7. Ward JF. Can PSA velocity serve as a surrogate endpoint in trials of hormone-refractory, metastatic prostate cancer? Nat Clin Pract Urol. 3/6:310-1, 6/2006.
8. Ward JF. Salvage Radiotherapy for PSA-only Recurrence. The American Journal of Urology Review 3:366-374, 10/2005.
9. Ward JF, Moul JW. Treating the biochemical recurrence of prostate cancer after definitive primary therapy. Clin Prostate Cancer 4/1:38-44, 6/2005.
10. Ward JF, Blute ML, Bergstralh EJ, Slezak JM, Zincke H. Radical Prostatectomy for clinically advanced (ct3) prostate cancer in the PSA era: 15-year outcomes. J Urol 173(4):224-224, 04/01/2005, 4/2005.
11. Ward JF, Slezak J, Blute ML, Bergstralh EJ, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int. 95/6:751-6, 4/2005.
12. Ward JF, Moul JW. Rising prostate-specific antigen after primary prostate cancer therapy. Nat Clin Pract Urol. 2/4:174-82, 4/2005.
13. Ward JF, Sebo TJ, Blute ML, Zincke H. Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J Urol. 173/4:1156-60, 4/2005.
14. Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Blute ML. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol 172/6 Pt 1:2244-8, 12/2004.
15. Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Myers RP, Blute ML. The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy. J Urol 172/4 Pt 1, 10/2004.
16. Ward JF, Blute ML. Use and timing of radiotherapy in high-risk prostate cancer. JAMA 291/23:2817: author reply 2817-8, 6/2004.
17. Ward JF, Bartsch G, Sebo TJ, Pinnggera GM, Blute ML, Zincke H. Pathologic characterization of prostate cancers with very low serum prostate specific antigen (0-2 ng/mL) incidental to cystoprostatectomy: is PSA a useful indicator of clinical significance? Urol Oncol 22/1:40-7, 2/2004.
18. Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatecomy. J Urol 170/5:1872-6, 11/2003.
19. Ward JF, Zincke H. Radical prostatectomy for the patient with locally advanced prostate cancer. Curr Urol Rep 4/3:196-204, 6/2003.
20. Ward JF, Zincke, Slezak J, Bergstralh EJ, Blute Ml. Calculated Prostate Specific Antigen Doubling Time Subsequent to Radical Prostatectomy as a Predictor of Response to Salvage Pelvic Radiotherapy. J Urol 169(4):278, 04/01/2003, 4/2003.
21. Ward JF, Blute JL, Slezak J, Bergstralh EJ, Zincke H. Long-Term (>5 years) biological pattern of clinically recurrent prostate cancer subsequent to radical prostatectomy. Journal of Urology 169(4):71-71, 04/01/2003, 4/2003.
22. Ward JF, Zincke H, Sebo TJ, Blute ML. Salvage Surgery for radiorecurrent prostate cancer: Outcomes and Complications from a 30-year experience. J Urol. 169(4):397, 04/01/2003, 4/2003.
23. Ward JF, Blute ML, Bergstralh EJ, Slezak J, Zincke. The Impact of Nerve Sparing Versus Wide Local Excision on Margin Positive Rates During Radical Prostatectomy. Journal of Urology 169(4):180-180, 04/01/2003, 4/2003.
24. Gray Sears CL, Ward JF, Sears ST, Puckett MF, Kane CJ, Amling CL. Prospective comparison of computerized tomography and excretory urography in the initial evaluation of asymptomatic microhematuria. J Urol 168(6):2457-60, 12/2002.
25. Zincke H, Ward JF. Outcome of Laparoscope Radical and Open Partial Nephrectomy for the Sporadic 4cm. or Less Renal Tumor with a Normal Contralateral Kidney. J Urol 168(4):1359-1360, 10/01/2002, 10/2002.
26. Ward JF, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. The influence of pNx/pN0 grouping in a multivariate setting for outcome modeling in patients with clear cell renal cell carcinoma. J Urol 168/1:56-60, 7/2002.
27. Ward JF, Pinggera GM, Zincke H, Bartsch G. Clinical and Pathological Characterization of Non-Palpable Prostate Cancer in a very low PSA range (0-2ng/ml). Journal of Urology 167(4):71-72, 04/01/2002, 4/2002.
28. Kane CJ, Tarman GJ, Summerton DJ, Buchmann CE, Ward JF, O'Reilly KJ, Ruiz H, Thrasher JB, Zorn B, Smith C, Morey AF. Multi-institutional experience with buccal mucosa onlay urethroplasty for bulbar urethral reconstruction. J Urol 167/3:1314-7, 3/2002.
29. Amling CL, Kane CJ, Riffenburgh RH, Ward JF, Roberts JL, Lance RS, Friedrichs PA. Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology 58/5:723-8, 11/2001.
30. Borboroglu PG, Amling CL, Schenkman NS, Monga M, Ward JF, Piper NY, Bishoff JT, Kane CJ. Ureteral stenting after ureteroscopy for distal ureteral calculi: a multi-institutional prospective randomized controlled study assessing pain, outcomes and complications. J Urol 166/5:1651-7, 11/2001.
31. Ward JF, Mouquin RR, Maurer ST. Expanding the differnetial diagnosis of the acute scrotum: ventriculoperitoneal shunt herniation. Urology 58/2:281, 8/2001.
32. Ward JF, Sands JP, Nowacki M, Amling CL. Malignant cytological washings from prostate specimens: an independent predictor of biochemical progression after radical prostatectomy. J Urol 165/2:469-73, 2/2001.
33. Ward JF, Cilento BG, Jr., Kaplan GW, Velling TE, Puckett M, Stock J. The ultrasonic description of postpubertal testicles in men who have undergone prepubertal orchiopexy for cryptorchidism. J Urol 163/5:1448/50, 5/2000.
34. Borboroglu PG, Kane CJ, Ward JF, Roberts JL, Sands JP. Immediate and postoperative complications of transurethral prostatectomy in the 1990's. J Urol 162/4:1307-10, 10/1999.
35. Ward JF, Johnstone PA, Kane CJ. Free-to-total prostate-specific antigen ratios 18-24 months following external beam radiation for adenocarcinoma of the prostate. J Surg Oncol. 70/2:91-4, 2/1999.
36. Gray C, Ward JF, Sands JP. Syncope from increased ventricular response in atrial fibrillation during voiding: a new indication for surgical management in benign prostatic hyperplasia. J Urol. 161/2:606-7, 2/1999.
37. Ward JF, Kaplan GW, Mevorach R, Stock JA, Cilento BG, Jr. Refined microscopic urinalysis for red blood cell morphology in the evaluation of asymptomatic microscopic hematuria in a pediatric population. J Urol. 160/4:1492-5, 10/1998.
38. Ward JF, Friedlander SF, Kaplan GW. Hemangioma presenting as an ulceration of the scrotum. J Urol. 160/1:182-3, 7/1998.
39. Gentle DL, Stoller ML, Jarrett TW, Ward JF. Protease inhibitor-induced urolithiasis. Urology 50/4, 10/1997.
40. Ward JF, Nowacki M, Sands JP, Conner RJ, Huisman TK. Malignant cytological washings from radical prostatectomy specimens: a possible mechanism for local recurrence of prostate cancer following surgical treatment of organ confined disease. J Urol 156/4:1381-4: discussion 1384-5, 10/1996.
41. Duff DW, Fitzgerald D, Kullman D, Lipke DW, Ward JF. Blood Volume and Red Cell Space in Tissues of the Rainbow Trout, Salmo Gairdneri. Comparative Biochemistry and Physiology A 87:393-398, 1987.
42. Duff DW, Olson KR, Ward JF. Vascular and Renal Responses to Atrial Natriuretic Factor and Heart Extracts. American Journal of Physicology 251:R639-642, 1986.

Invited Articles

1. Ward J, Vogelzang N, Davis B. Management of Locally Advanced Prostate Cancer I. Up To Date Journal 14(2), 08/2009, 8/2009.
2. Ward J, Vogelzang N, Davis B. Management of Locally Advanced Prostate Cancer II. Up To Date Journal 14(2), 08/2009, 8/2009.
3. Ward J, Vogelzang N, Davis B. Management of Locally Advanced Prostate Cancer III. Up To Date Journal 14(2), 08/2009, 8/2009.
4. Ward JF, Pisters LL, Pagliaro LC. Salvage Therapy for Radiorecurrent Prostate Cancer. Curr Probl Cancer 32:242-271, 8/2008.
5. Ward JF, Vogelzang N. Management of locally advanced (T3) prostate cancer. UpToDate 2006, 2007.
6. Ward JF, Vogelzang N, Davis B. Management of locally advanced (T3) prostate cancer II. UpToDate, 2007.
7. Moul JW, Ward JF. Management of the patient with a rising PSA alone. Hematol Oncol Clin N AM 20/4:897-908, 8/2006.
8. Freedland SJ, Ward JF. PSA recurrence of prostate cancer--Update 2006. Issues in Urology 18/3:109-18, 5/2006.
9. Ward JF. Salvage Radiotherapy for PSA-Only Recurrence. The American Journal of Urology Review 3/8, 8/2005.
10. Ward JF, Moul JW. Biochemical recurrence after definitive prostate cancer therapy. Part I: defining and localizing biochemical recurrence of prostate cancer. Curr Opin Urol. 15/3:181-6, 5/2005.
11. Young CY, Jatoi A, Ward JF, Blute ML. The effects of dietary factors on the androgen receptor and related cellular factors in prostate cancer. Curr Med Chem 11/7:909-23, 4/2004.
12. Ward JF, Blute ML. Chemoprevention of prostate cancer. Expert Rev Anticancer Ther. 3/2:203-14, 4/2003.
13. Ward JF, Amling CL, McKusick MA. The Use of Percutaneous Transcatheter Embolization in Urology. AUA Update Series 22/Lesson 39:309-320, 2003.
14. Ward JF, Velling TE. Transcatheter therapeutic embolization of genitourinary pathology. Reviews in Urology 2:236-245, 10/2000.
15. Ward JF, Gray C. Increased Ventricular Response in Atrial Fibrillation During Voiding: A New Indication for Surgical Management of Bening Prostatic Hypertrophy. Cardiology Review Series 2100:10-11, 2000.
16. Ward JF, Velling TE. Transcatheter Therapeutic Embolization of Genitourinary Pathology. Reviews in Urology 2/4:236-245, 2000.

Editorials

1. Margulis V, Ward JF. A Comparison of American Joint Committee on Cancer Pathologic Stage T3a versus T3b urothelial carcinoma: Analysis of patient outcomes. CANCER. In Press.
2. Ward JF, Jones JS. Classification System: Organ Preserving Treatment for Prostate Cancer. J Urol. In Press.
3. Ward JF, Vogelzang N. Management of locally advanced (T3) prostate cancer. Up To Date Journal, 8/2009.
4. Ward JF. Delay of Radical Prostatectomy and Risk of Biochemical progression in men with low Risk Prostate Cancer. J Urol 175(4):1298-1303; Editorial Comments 1303A, 2006.
5. Ward JF. Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma. Cancer/Nature Clinical Practice Urology, Summer 2006 106:63-67, 2006.
6. Ward JF. Salvage radical prostatectomy: Quality of Life outcomes and long-term oncologic control of radiorecurrent prostate cancer. Journal of Urology 176(5):2025-2032 2032 A, 2006.
7. Ward JF. Comments on "single-strand-specific radiosensitization by bromodeooxyuridine" by Cecchini et al. Radiat Res. 164(3):341-2, Sep 2005, 9/2005.
8. Ward JF, Zincke H. Radical Cystectomy with Preservation of Sexual Function and Urinary Continence: Description of A New Technique. International Brazilian Journal of Urology 29/3, 2003.
9. Ward JF, Zincke H. Outcome of Laparoscopic Radical and Open Partial Nephrectomy for the Sporadic 4 Cm. or Less Renal Tumor with a Normal Contralateral Kidney. J Urol 168/4 Pt 1:1356-9; Editorial Comments 1359-60, 2002.
Other Articles
1. Hoseman S, Ward JF, Kuban DA. Organ-Confined Prostate Cancer. OncoLog 54(4):4-6, 04/2009, 4/2009.
2. Ward JF. Prostate Cancer, PSA, and questions that can only be answered by clinical trials-The Moul/Banez/Freedland Article Reviewed. Oncology-New York 12:1452, 11/01/2007, 11/2007.

Abstracts

1. Davis JW, Troncoso P, Ward JF, Pettaway CA, Pisters LL, Kuban D, Brown V, Logothetis C, Kim J. Active surveillance for localized prostate cancer - A prospeective protocol. Journal of Urology 181:494A, 4/2009.
2. Ward JF, Brown SCW, Chaussy C, Conti GN, Eastham JA, Ganzer R, Gelet A, Murat J, Rebillard X, Rewcastle JC, Robertson CN, Thueroff S, Blana A. Correlation of biochemical events and clinical failure following high intensity focused ultrasound of the prostate: The Stuttgart Definition. Journal of Urology 181:636A, 4/2009.
3. Ward JF, Graefen M, Huland H, Kollermann J, Sauter G, Wang XM, Haese A, Troncoso P, Babaian RJ, Chun FKH. PCA3 score based nomogram to predict low-volume/low-grade prostate cancer in radical prostatectomy specimens. Journal of Urology 181:155, 4/2009.
4. Dhar N, Cher ML, Pisters LL, Ward JF, Jones JS. Primary full gland prostate cyroablation: Updated results from 3209 patients tracked with the COLD registry. Journal of Urology 181:631A, 4/2009.
5. Blana A, Borwn SCW, Chaussy C, Conti GN, Eastham JA, Ganzer R, Murat FJ, Rebillard X, Rewcastle JC, Robertson CN, Thueroff S, Ward Jf, Gelet A. Primary prostate HIFU without pretreatment hormone therapy: Biochemical survival of 468 patients tracked with the @-registry. Journal of Urology 181:635A, 4/2009.
6. Chun FKJ, Ward JF, Huland H, Kollermann J, Sauter G, Graefen M, Troncoso P, Babaian RJ, Haese A. Prostate Cancer Antigen 3 (PCA3) shows significant association to prostate cancer volume but no correlation to total prostate volume or serum prostate specific antigen. Journal of Urology 181:2127A, 4/2009.
7. Dhar N, Cher ML, Levy DA, Pisters LL, Ward JF, Jones JS. Salvage prostate cryoablation: Updated results from 445 patients tracked with the COLD registry. Journal of Urology 181:1976A, 4/2009.
8. Parker PA, Latini DM, Ward JF, Pettaway CA, Pisters LL, Matin SF, Frank SJ, Brown V, Kuban DA, Logothetis CJ, Kim J, Davis JW. Associations Between Uncertainty, Anxiety, and Quality of Life in Men with Prostate Cancer on Active Surveillance. Annals of Behavioral Medicine (Suppl):37A, 03/2009, 3/2009.
9. Biana A, Brown SCW, Chaussy C, Conti GN, Eastham JA, Ganzer R, Gelet R, Murat FJ, Rebilliard S. RoRobertson CN, Thueroff S, Ward JF, Rewcastle JC. Defining biochemical failure following high intensity focused ultrasound of the prostate: The Stuttgart Definition. European Urology Supplements, 3/2009.
10. Blana A, Brown SCW, Chaussy C, Conti GN, Eastham JA, Ganzer R, Murat FJ, Rebilliard X, Rewcastle JC, Robertson CN, Thueroff S, Ward JF, Gelet A. Primary prostate HIFU without pretreatment hormone therapy: Biochemical survival of 763 patients tracked with the @-registry. European Urology Supplements, 3/2009.
11. Ward JF, Chun F, Fraefen M, Huland H, Kollermann J, Sauter G, Babaian RJ, Haese A. Prostate Cancer Antigen 3 (PCa3) is an independent and significant predictor for pathologically insignificant Prostate Cancer (PCa) in men undergoing radical prostatectomy. European Urology Supplements, 3/2009.
12. Chun F, Ward JF, Huland H, Kollerman J, Sauter G, Graefen M, Babain RJ, Haese A. Prostate cancer antigen 3 (PCa3) shows significant association to prostate cancer volume (PCaV) but no correlation to total prostate volume or serum prostate specific antigen (PSA) and separates patholologically insignificant from significant prostate cancer (PCa) in men undergoing radical prostatectomy. European Urology Supplements, 3/2009.
13. Ward JF, Nakanishi H, Babaian RJ, Troncoso P. In-Field/Out Field Prostate Cancer Foci: Multifocality and Considerations for the Application of Focal Prostate Therapy. Duke Abstracts -1st Int'l Workshop on Focal Therapy & Imaging of Prostate Cancer, 02/2009, 2/2009.
14. Ward JF. Evaluation of Regionally Ablative Templates (Hockey Stick and Hemiprostate) Applied to Prostatectomy Specimens From Men with Unilaterally Positive Biopsies. 2008 American Radium Society Annual Meeting, 05/2008, 5/2008.
15. Troncoso P, Davis JD, Ward JF, Wang X, Babaian RJ, Kim J. Prostatectomy findings in patients considered potential candidates for active surveillance. Modern Pathology 21:185A, 01/08/08, 1/2008.
16. Troncoso P, Davis JW, Ward JF, Wang X, Babaian RJ, Kim J. Radical Prostatectomy findingd in patients considered potential candidates for active surveillance. Laboratory Investigation 88:185A, 01/08/08, 1/2008.
17. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical Prostatectomy for Clinically Advanced (cT3) Prostate Cancer in the PSA Era: 15-Year Outcomes. Journal of Urology:42A, 5/2005.
18. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical Prostatectomy for Clinically Advanced (cT3) Prostate Cancer in the PSA Era: 15-Year Outcomes. Kimbrough Urologic Meeting (#96):96A, 1/2005.
19. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical Prostatectomy for Clinically Advanced (cT3) Prostate Cancer in the PSA Era: 15-Year Outcomes. Society of Urologic Oncology Meeting (#44):44A, 12/2004.
20. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical Prostatectomy for Clinically Advanced (cT3) Prostate Cancer in the PSA Era: 15-Year Outcomes. Young Urologic Oncologists Meeting, 12/2004.
21. Ward, JF. Calculated prostate specific antigen doubling time subsequent to radical prostatecomy as a predictor of response to salvage pelvic radiotherapy. Journal of Urology, 4/2003.
22. Ward JF. Does DNA ploidy and nuclear morphometry add to outcome prediction models for patients with completely resected pT1 conventional cell carcinoma of the kidney?. Journal of Urology:1015A, 4/2003.
23. Ward JF. Long-term (>5 years) biological pattern of clinically recurrent prostate cancer subsequent to radical prostatectomy. Journal of Urology:275A, 4/2003.
24. Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Blute ML. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. Association 101st Meeting (#1079):1079A, 4/2003.
25. Ward JF. Salvage Surgery for Radiorecurrent Prostat Cancer: Outcomes and Complications from a 30 Year Experience. Journal of Urology:1484A, 4/2003.
26. Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Myers RP, Blute ML. The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy. Journal of Urology 693A, 4/2003.
27. Ward JF. Long Term (>5 years) biological pattern of clinically recurrent prostate cancer subsequent to radical prostatectomy. Society of Urologic Oncologists, 3rd Annual Meeting, 12/2002.
28. Ward JF. Prostate Cancer imaging in Murine Model using Carbon-11 Labeled Choline and Acetate. Academy of Molecular Imaging (#136):136A, 10/2002.
29. Ward JF. Salvage Surgery for Radiorecurrent Prostat Cancer: Outcomes and Complications from a 30 Year Experience. North Central Section of the AUA 76th Meeting:30A, 9/2002.
30. Ward JF. Prostate Cancer imaging in Murine Model Using Carbon-11 Labeled Choline and Acetate. Molecular Imaging and Biology 4/4 Supplement 1:35A, 8/2002.
31. Ward JF. Clinical and Pathologic Characterization of Non-palpable Prostat Cancer in a very low PSA Range (0-2ng/ml). Journal of Urology:283A, 5/2002.
32. Ward JF. Expanding the Differential Diagnosis of the Acute Scrotum: Ventriculoperitoneal Shunt Herniation. Kimbrough Urological Seminar (#88):88A, 1/2001.

Book Chapters

1. Zurita AJ, Ward JF, Kim J. Targeted Therapy in Prostate Cancer. In: Targeted Therapy in Cancer. Ed(s) R Kurzrock, M Markman. Humana Press: USA, 289-304, 2008.
2. Rini BJ, Ward JF, Vogelzang NJ. Primary Neoplasms of the Kidney and Renal Pelvis. In: Disease of the Kidney and Urinary Tract, 8th. Ed(s) RW Schrier. Lippincott Williams & Wilkins: Philadelphia, PA, 2006.
3. Ward JF, Borboroglu PG. Stones. In: Aging. Ed(s) P Roberts. Salem Press: Pasadena, CA, 719-722, 2000.
4. Ward JF, Bretan PJ. Epitaxy. In: Magill's Survey of Science: Physical Science Series. Ed(s) JTA Tombrello. Salem Press: Pasadena, CA, 2917-2921, 1998.

Letters to the Editor

1. Ward JF, Blute ML. Use and timing of radiotherapy in high-risk prostate cancer. JAMA 291(23):2817, 6/2004.

Manuals, Teaching Aids, Other Teaching Publications

1. Ward JF, Blute ML. Mayo Clinic on Prostate Health, 2nd. Ed(s) ML Blute, JF Ward. Mayo Clinic Health Information: Rochester, MN, 2003.

Last updated: 8/1/2013